Text Size

National Survey on Infiltrative Breast Cancer (CSI)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00696527
First received: June 10, 2008
Last updated: December 9, 2010
Last verified: December 2010
History of Changes
  Purpose

The purpose of this observational study is to describe radiological, clinical and histological characteristics of women with infiltrative breast cancer.


Condition
Infiltrative Breast Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: National Prospective Survey on Women With a Diagnosis of Infiltrative Breast Cancer

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Radiological, Clinical and Histological characteristics [ Time Frame: Once ]

Secondary Outcome Measures:
  • Treatments: Surgery, radiotherapy, chemotherapy, hormonotherapy. [ Time Frame: Once ]

Estimated Enrollment: 1500
Study Start Date: June 2007
Study Completion Date: July 2008
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

First ten consecutive women with infiltrative breast cancer seen by oncologists, and fulfilling eligibility criteria.

Criteria

Inclusion Criteria:

  • Women> or = 18 years old
  • Women with newly diagnosis of infiltrative breast cancer
  • Agree to take part in this study

Exclusion Criteria:

  • Women with other malignant tumor (except in situ cervical carcinoma or treated basal cell carcinoma)
  • Women with in situ ductal carcinoma or in situ lobular carcinoma
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00696527

  Show 136 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Alain Castaigne, Medical Director AstraZeneca
  More Information

No publications provided

Responsible Party: Alain Castaigne, Medical Director, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00696527     History of Changes
Other Study ID Numbers: NIS-OFR-DUM-2007/1
Study First Received: June 10, 2008
Last Updated: December 9, 2010
Health Authority: France: French Data Protection Authority

Keywords provided by AstraZeneca:
Infiltrative breast cancer-Clinical practice
Women with infiltrative breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases

ClinicalTrials.gov processed this record on May 19, 2013